Viatris Inc. (NASDAQ:VTRS) is a familiar name in the pharmaceutical industry, with a portfolio that stretches from branded medications to generics and fresh, innovative therapies. Its broad reach and diverse lineup help bring in steady revenue year after year. Still, the company faces heavy competition, persistent price pressures, and the ongoing risk of losing exclusivity on important products. These realities make it challenging for the company to generate reliable earnings growth, especially compared with established dividend payers featured in Top 10 Unstoppable Dividend Stocks to Buy.
Recent results give shareholders some cautious optimism. In the second quarter of 2026, Viatris reported a 5% increase in revenue year-over-year, reaching $3.76 billion. Adjusted EPS jumped 11% to $0.69, and adjusted EBITDA also rose 10% to $1.19 billion. Despite these gains, Viatris still ended the quarter with a GAAP net loss of $119 million. This contrast shows how the company’s adjusted operating performance can look much stronger than its actual bottom-line profit.
Looking ahead, Viatris is aiming higher, bumping its 2026 adjusted EPS guidance up to a range between $2.45 and $2.59, with the midpoint at $2.52. That is an encouraging sign for the company’s earnings outlook. Even so, it is important for investors to remember that adjusted earnings leave out certain costs and charges, so the growth rate in these numbers does not always line up with what you see in the official GAAP profits.
Find VTRS among 10 Best US Stocks to Buy Under $20: Ranked by Hedge Funds
Taking a Closer Look at Valuation
Viatris Inc. traded at a forward P/E ratio of 6.38. The trailing P/E is not very useful in this case, since the company’s recent earnings were negative. This forward multiple works out to an earnings yield of about 15.7%, which is well above the 5.1% yield on the 10-year U.S. Treasury as of October 19. That kind of difference tends to catch investors’ attention.
That gap may look appealing at first glance, but it is important to keep in mind that this is not a perfect comparison. Treasury interest is guaranteed, while company earnings can fall and are not always passed along to shareholders as dividends.
Looking back, Viatris was trading at forward multiples closer to 5 times earnings in 2024 and 2025. The fact that today’s multiple is higher suggests that investors are a bit more optimistic about the company’s prospects than they were a couple of years ago.
For comparison, Teva Pharmaceutical Industries had a forward P/E of 12.55 in September 2026. This shows that the market is willing to pay more for Teva’s future earnings than for those of Viatris. There are understandable reasons behind this discount. The company is up against strong competition for its older products, must deal with patent expirations, and is under pressure to cut prices. On top of that, ongoing GAAP losses make it harder to get a clear read on overall profitability. The main question is whether Viatris can keep growing its adjusted EPS once the current recovery phase is over. If earnings stall or if acquisitions and restructuring keep adding costs, then the stock’s low valuation may turn out to be less of a bargain than it seems.
Also read: Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
Dividend: A Steady Payout, but Not the Full Picture
Viatris pays a quarterly dividend of $0.12 per share, or $0.48 annually. With shares trading between $17 and $18, investors are getting a dividend yield of roughly 2.7 to 2.8%. Based on management’s 2026 adjusted EPS target of $2.52, the annual dividend payout ratio comes to about 19%. That leaves Viatris with ample room to keep making distributions while also reinvesting in the business. The company also brought in $329 million in free cash flow in the second quarter and reduced its gross leverage ratio to 2.9 times. For a broader comparison of dividend opportunities, the unstoppable dividend stocks list highlights other companies to consider alongside Viatris, particularly when dividend growth is just as important as the current yield.
Even so, it is important to remember that adjusted EPS is not the same thing as cash flow, and paying down debt is still a key priority for Viatris. Setbacks such as manufacturing issues, regulatory delays, or weaker product demand could make it harder to maintain the current dividend. Since 2022, the annual dividend has stayed flat at $0.48, so income growth has not really contributed much to shareholder returns.
Conclusion
Viatris stands out for offering investors a high earnings yield and a modest, well-covered dividend. The stock’s valuation leaves the door open for future gains if the company can keep growing its earnings and paying down debt. Still, there are real business risks that help explain why the stock trades at a discount. For most investors, VTS is best viewed as a play on income and recovery, rather than a guaranteed source of steady dividend growth.
READ NEXT: Merck’s 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery? and Target (TGT) Has an Income Story. Does It Also Have a Growth Story?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center